TIGIT and small cell lung carcinoma: The SKYSCRAPER-02 trial was a randomized, double-blinded, phase III trial, which compared tiragolumab (a TIGIT inhibitor) plus atezolizumab and EP with atezolizumab plus EP as first-line treatment for ES-SCLC (20).